mutant mhc class ii epitopes drive therapeutic immune responses cancer
tumour-specific mutations ideal targets cancer immunotherapy lack expression healthy tissues can potentially recognized neo-antigens mature t-cell repertoire systematic targeting vaccine approaches however hampered fact every patients tumour possesses unique set mutations mutanome must first identified recently proposed personalized immunotherapy approach target full spectrum patients individual tumour-specific mutationsl show three independent murine tumour models considerable fraction non-synonymous cancer mutations immunogenic unexpectedly majority immunogenic mutanome recognized cal+ t cells vaccination cal+ immunogenic mutations confers strong antitumour activity encouraged findings established process mutations identified exome sequencing selected vaccine targets solely bioinformatic prioritization basis expression levels major histocompatibility complex mhc class ii-binding capacity rapid production synthetic poly-neo-epitope messenger rna vaccines show vaccination polytope mrna vaccines induces potent tumour control complete rejection established aggressively growing tumours mice moreover demonstrate cal+ t cell neo-epitope vaccination reshapes tumour microenvironment induces cytotoxic t lymphocyte responses independent immunodominant antigen mice indicating orchestration antigen spread finally demonstrate abundance mutations predicted bind mhc class ii human cancers well employing predictive algorithm corresponding human cancer types thus tailored immunotherapy approach introduced may regarded universally applicable blueprint comprehensive exploitation substantial neo-epitope target repertoire cancers enabling effective targeting every patients tumour vaccines produced just time
